# A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants

> **NCT06281158** · PHASE1 · COMPLETED · sponsor: **Denali Therapeutics Inc.** · enrollment: 7 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** [14C]-DNL343

## Key facts

- **NCT ID:** NCT06281158
- **Lead sponsor:** Denali Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-01
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2024-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06281158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06281158, "A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT06281158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*